Therapeutic Pipeline - Overview
A variety of drugs are required for the treatment of the numerous types of cancer. Different cancers respond differently to therapeutics. Even different patients with the same cancer type respond differently to the same drug. In some cases, cancer cells develop a resistance to drugs which are initially effective in treating the disease. To address these challenges, BioApex is developing a portfolio of targeted small molecule drugs to provide the most effective therapy for each cancer type. Three of these agents are currently being evaluated in preclinical trials.
BioApex owns and licenses proprietary platform technologies that are targeted at small molecule therapeutics. We plan to initially advance to clinical testing a group of promising compounds on which the design, in vitro testing and preclinical trials have been completed. With our limited resources focused on research and development, our tiered strategy - with some compounds in an advanced stage of development and encouraging results to date, and some compounds in the pipeline for development - is positioned to attract industry “partners,” governmental grants, loans and private equity. Generally, we plan to cooperate and partner with strong pharmaceutical companies that have established distribution channels in our target areas.
Therapeutic Pipeline - Small Molecules
BioApex’s development focus is on “small molecules”. Small molecules are a diverse group of natural and synthetic substances that generally have a low molecular weight and are either isolated from natural sources such as plants, fungi or microbes or synthesized by organic chemistry. Most conventional pharmaceuticals, such as aspirin, penicillin and chemotherapeutics, are small molecules.
We own a proprietary portfolio of a small generation, low molecular weight compounds derived from natural plant products. Our intellectual property addresses the very broad fields of cell cycle and senescence related disorders and, besides cancers, include aging and skin disorders. We believe that to date, there are no commercially available compounds that combine the same mode of action, effectiveness and minimal side effects.
